Nautilus Biotechnology, Inc.

Ladies and gentlemen, thank you for standing by. Your conference call should begin momentarily. Thank you. Thank you. Thank you. Thank you. Thank you for standing by and welcome to the Nautilus Q1 2022 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question at that time, please press star then 1 on your touchtone telephone. As a reminder, today's conference call is being recorded. I will now return the conference to the host, Mr. Alex Conn, with investor relations. So you may begin.

Thank you. Earlier today, Nautilus released financial results for the quarter ended March 31, 2022. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelation at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as it's live broadcast May 3rd, 2022. With that, I'll turn the call over to Sujal.

Thanks, Alex. Good morning, and thank you to everyone for joining us on the call. Today, we will review our results for the first quarter of 2022 and provide an update on a range of recent scientific and related activities. My remarks will be relatively brief, as Parag has much to share with you. I'll begin by thanking our teams in the Bay Area and Seattle for their dedication and hard work again this quarter. Because of their efforts, we've continued to make strong progress against our key scientific and business goals. Each scientific objective we reach and each business milestone we achieve gets us one step closer to our ultimate purpose of improving the lives and health of people around the world. By providing ubiquitous access to the proteome, we expect to expand countless research horizons and enable boundless scientific exploration and discovery. Our team of scientific and engineering innovators is fully aligned towards and committed to realizing these important objectives. Now, more than ever, we believe Nautilus has the potential to revolutionize biomedical research by unlocking the potential of the proteome. The world needs a dramatic acceleration in target identification and therapeutic development, but researchers have been hobbled by the lack of sensitivity, scale, and reproducibility of both traditional and emerging approaches. We believe a bold scientific leap is required to overcome these limitations and to radically reinvent proteomics, something we continue to view as one of the last and most significant untapped opportunities in biological science today. We envision powerful research uses for our platform. For example, proteomics could make it possible for researchers to more quickly identify the mechanistic origins of diseases ranging from cancer to Alzheimer's. Understanding those mechanisms is key to identifying effective treatments. We also envision the platform being used to identify biomarkers which are able to stratify patients by disease severity or by which treatments are most likely to be effective. As physicians and researchers use advanced proteomics technologies to catalog the proteomes of more and more diseases, they'll be able to identify molecular targets for therapeutics with higher likelihoods of success, create new protein-based diagnostic tools, better understand mechanisms of drug resistance, and more precisely monitor therapeutic effectiveness. When richer proteomic data begins to drive deeper research insights, we foresee significant increases in patient well-being and health. A key to our continued success will be scaling up a world-class team across a broad range of disciplines and keeping that team laser-focused on our long-term mission. One of Nautilus' superpowers is the deep integration of capabilities across life sciences, computer and data sciences, and physical sciences and engineering. The heart of those engines is our talented team and their dedication to Nautilus is critically important and will create a clear point of competitive differentiation for us in the long run. I'm pleased to report that we have hired Gwen Weld as our Chief People Officer to lead our continued scale-up, to deepen our existing high-performance culture, and to do so in a way that creates an inclusive, driven, and highly collaborative work environment. Gwen and I have worked closely together in the past and I've seen firsthand the type of impact she can have on an organization. I'm pleased that she has chosen to join us and could not be more excited about the opportunities for success that lie ahead. When I look back on the progress made in Q1 and the successes of the year leading up to it, I'm struck by how far we've come in such a short period of time. In 2021, we began our journey as a publicly traded company, announced a strategic partnership with APCAM, and signed research collaborations with Amgen and the University of Texas MD Anderson Cancer Center, along with our ongoing work with Genentech. But these exciting developments are only the beginning, and as we look ahead to the remainder of 2022 and beyond, we're excited to have you along on this journey with us and look forward to updating you on our progress along the way. I'll now turn the call over to Parag for an update on our research and development activities. Parag?